A Phase 1-2 Open-Label Dose-Finding Proof of Concept First-in-Human Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors
Brief description of study
If you have an advanced or recurrent solid tumor in one of the following cancer types: breast cancer, castration-resistant prostate cancer, non-small cell lung cancer, epithelial ovarian cancer, endometrial cancer, head and neck squamous cell cancer or cholangiocarcinoma (bile duct cancer) you may qualify to participate in a study evaluating the investigational drug CX-2009. The goal of this phase 1/2 study is to evaluate the possible side effects, safety and tolerability of CX-2009 when given alone in patients with selected advanced or recurrent solid tumors.
Clinical Study Identifier: s17-00690
ClinicalTrials.gov Identifier: NCTs17-00690
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
